Peter Campochiaro MD

Professor of Ophthalmology

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. Campochiaro PA, Marcus DM, Awh CC, Regillo C, Adamis AP, Bantseev V, Chiang Y, Ehrlich JS, Erickson S, Hanley WD, Horvath J, Maass KF, Singh N, Tang F, Barteselli G. Ophthalmology. 2019 Apr 1. pii: S0161-6420(18)33328-1. doi: 10.1016/j.ophtha.2019.03.036. PMID: 30946888 

Metipranolol promotes structure and function of retinal photoreceptors in the rd10 mouse model of human retinitis pigmentosa. Kanan Y, Khan M, Lorenc VE, Long D, Chadha R, Sciamanna J, Green K, Campochiaro PA. J Neurochem. 2019 Jan;148(2):307-318. doi: 10.1111/jnc.14613. Epub 2018 Dec 3. PMID: 30315650

Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection. Zhang Y, Bazzazi H, Lima E Silva R, Pandey NB, Green JJ, Campochiaro PA, Popel AS. Invest Ophthalmol Vis Sci. 2018 Oct 1;59(12):5266-5276. doi: 10.1167/iovs.17-23632. PMID: 30383198

AAV8-antiVEGFfab Ocular Gene Transfer for Neovascular Age-Related Macular Degeneration. Liu Y, Fortmann SD, Shen J, Wielechowski E, Tretiakova A, Yoo S, Kozarsky K, Wang J, Wilson JM, Campochiaro PA. Mol Ther. 2018 Feb 7;26(2):542-549. doi: 10.1016/j.ymthe.2017.12.002. Epub 2017 Dec 8. PMID: 29292162

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial. Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA. Lancet. 2017 Jul 1;390(10089):50-61. doi: 10.1016/S0140-6736(17)30979-0. Epub 2017 May 17. Erratum in: Lancet. 2017 Jul 1;390(10089):28. PMID: 28526489

The Nicotinic Cholinergic Pathway Contributes to Retinal Neovascularization in a Mouse Model of Retinopathy of Prematurity. Hackett SF, Seidel C, Abraham S, Chadha R, Fortmann SD, Campochiaro PA, Cooke JP. Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1296-1303. doi: 10.1167/iovs.16-20670. PMID: 28241318

Tyrosine kinase blocking collagen IV-derived peptide suppresses ocular neovascularization and vascular leakage. Silva RLE, Kanan Y, Mirando AC, Kim J, Shmueli RB, Lorenc VE, Fortmann SD, Sciamanna J, Pandey NB, Green JJ, Popel AS, Campochiaro PA. Sci Transl Med. 2017 Jan 18;9(373). pii: eaai8030. doi: 10.1126/scitranslmed.aai8030. PMID: 28100839

The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization. Zeng M, Shen J, Liu Y, Lu LY, Ding K, Fortmann SD, Khan M, Wang J, Hackett SF, Semenza GL, Campochiaro PA. J Mol Med (Berl). 2017 Apr;95(4):417-429. doi: 10.1007/s00109-016-1498-9. Epub 2016 Dec 21. PMID: 28004126

Sustained delivery of a HIF-1 antagonist for ocular neovascularization. Iwase T, Fu J, Yoshida T, Muramatsu D, Miki A, Hashida N, Lu L, Oveson B, Lima e Silva R, Seidel C, Yang M, Connelly S, Shen J, Han B, Wu M, Semenza GL, Hanes J, Campochiaro PA. J Control Release. 2013 Dec 28;172(3):625-33. doi: 10.1016/j.jconrel.2013.10.008. Epub 2013 Oct 12. PMID: 24126220

Long-term suppression of ocular neovascularization by intraocular injection of biodegradable polymeric particles containing a serpin-derived peptide. Shmueli RB, Ohnaka M, Miki A, Pandey NB, Lima e Silva R, Koskimaki JE, Kim J, Popel AS, Campochiaro PA, Green JJ. Biomaterials. 2013 Oct;34(30):7544-51. doi: 10.1016/j.biomaterials.2013.06.044. Epub 2013 Jul 10. PMID: 23849876